Abstracts tagged "rheumatoid arthritis (RA) and treatment guidlelines"

Abstract Number: 601 • 2018 ACR/ARHP Annual Meeting
At Which Point and for Which Reasons Are Oral MTX Formulations Switched to Injectable Ones in RA Patients? Combined Results from 3 Independent Observational and Clinical Trials
René-Marc Flipo¹, Alain Saraux², Christophe Hudry³, Cécile Gaujoux-Viala⁴, Eric Senbel⁵, Sonia Tropé⁶, Elena Zinovieva⁷, Agnès Courbeyrette⁸ and Hélène Herman-Demars⁷, ¹Hôpital Roger Salengro, Lille, France, ²Rheumatology, CHU Brest, Brest, France, ³AP-HP Hôpital Cochin, Paris, France, ⁴Rheumatology, Nîmes University Hospital and EA2415 Montpellier University, Nîmes, France, ⁵Rheumatology office, Marseille, France, ⁶149 avenue du Maine, ANDAR, Paris, France, ⁷Medical Department Nordic Pharma, Paris, France, ⁸Medical Departement, Nordic Pharma, Paris, France
Background/Purpose: MTX is considered as a cornerstone in RA treatment since the 1990s and its injectable forms have proven their enhanced clinical and pharmacological efficacy…
Abstract Number: 1929 • 2018 ACR/ARHP Annual Meeting
The Neutrophil-Lymphocyte Ratio in Newly Diagnosed Rheumatoid Arthritis and Its Ability to Predict Treatment Failure
Daniel Boulos¹, Robert Metcalf², Susanna Proudman³ and Ian Wicks⁴, ¹Rheumatology, Royal Melbourne Hospital, Melbourne, Melbourne, Australia, ²Rheumatology, Royal Adelaide Hospital, Adelaide, Adelaide, Australia, ³Royal Adelaide Hospital, Rheumatology Unit and University of Adelaide, Discipline of Medicine, Adelaide, Australia, ⁴Wicks Lab, Walter and Eliza Hall Institute, Melbourne, Australia
Background/Purpose: To assess whether the neutrophil-lymphocyte ratio (NLR) can predict those who require disease modifying therapy escalation and hence progression in rheumatoid arthritis (RA). Methods:…
Abstract Number: 2319 • 2018 ACR/ARHP Annual Meeting
Adherence to Guideline Recommendations for Screening and Treatment of Glucocorticoid Induced Osteoporosis in Patients with Rheumatoid Arthritis on Long Term Glucocorticoid Therapy at a Tertiary Care Center
Patrick Webster¹ and Tarun S. Sharma², ¹Internal Medicine, Allegheny Health Network, Pittsburgh, PA, ²Rheumatology, Lupus Center of Excellence, Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Glucocorticoid induced osteoporosis (GIOP) is an under-recognized and under-treated condition. Many long-term glucocorticoid (GC) users never receive therapy to prevent bone loss or are…
Abstract Number: 2821 • 2018 ACR/ARHP Annual Meeting
Dose Tapering and Discontinuation of Biological Therapy in Rheumatoid Arthritis Patients in Routine Care – 2-Year Outcomes and Predictors
Cecilie Heegaard Brahe¹, Simon Krabbe¹, Mikkel Østergaard¹, Lykke Midtbøll Ørnbjerg¹, Daniel Glinatsi¹, Henrik Rogind¹, Hanne Slott Jensen², Annette Hansen³, Jesper Nørregaard⁴, Søren Jacobsen⁵, Lene Terslev¹, Tuan Khai Huynh⁴, Dorte Vendelbo Jensen⁶, Natalia Manilo², Karsten Asmussen², Per Brown-Frandsen⁵, Mikael Boesen⁷, Zoreh Rastiemadabadi⁷, Lone Morsel-Carlsen⁷, Jakob M. Møller⁸, Niels Steen Krogh⁹ and Merete Lund Hetland¹⁰, ¹Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark, ²Center for Rheumatology and Spine Diseases, Bispebjerg-Frederiksberg Hospital, Copenhagen, Copenhagen, Denmark, ³Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte, Gentofte, Denmark, Copenhagen, Denmark, ⁴Center for Rheumatology and Spine Diseases, Nordsjællands Hospital, Hillerød, Denmark, Hillerød, Denmark, ⁵Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ⁶Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Gentofte, Gentofte, Copenhagen, Denmark, ⁷Department of Radiology, Bispebjerg-Frederiksberg Hospital, Copenhagen, Copenhagen, Denmark, ⁸Department of Radiology, Copenhagen University Hospital Herlev, Copenhagen, Denmark, ⁹ZiteLab ApS, Copenhagen, Denmark, ¹⁰DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Glostrup, Denmark
Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care – 2-year outcomes and predictors Background/Purpose: A cohort of routine care…
Abstract Number: 2856 • 2018 ACR/ARHP Annual Meeting
Do Patients with Moderate or High Disease Activity Escalate RA Therapy According to Treat-to-Target Principles? Results from the Acr’s RISE Registry
Huifeng Yun¹, Lang Chen¹, Fenglong Xie¹, Himanshu Patel², Natalie Boytsov², Xiang Zhang² and Jeffrey R. Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Routine measurement of RA disease activity and adjustment of drug therapy to attain remission or low disease activity is recommended by the ACR and…
Abstract Number: 2955 • 2017 ACR/ARHP Annual Meeting
Does Guideline-Based Care Improve Outcomes That Matter to Patients? Tighter Control, Less Suffering, and Greater Well-Being over the Past Decade in Canadian RA Patients
Susan J. Bartlett^1,2, Orit Schieir³, Marie-France Valois⁴, Carol A Hitchon⁵, Janet E. Pope⁶, Gilles Boire⁷, Boulos Haraoui⁸, Edward C. Keystone⁹, Diane Tin¹⁰, Carter Thorne¹¹ and Vivian P. Bykerk¹², ¹Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁷Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁸Institute de Rheumatologie, Montreal, QC, Canada, ⁹University of Toronto, Toronto, ON, Canada, ¹⁰The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹University of Toronto, Newmarket, ON, Canada, ¹²2-005, Mt Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Best practice recommendations can increase quality of care and improve clinical outcomes, however the impact of recommendations on outcomes that matter most to patients…
Abstract Number: 645 • 2016 ACR/ARHP Annual Meeting
Prospective Observational Real-Life Study (STRATEGE) Shows the Efficacy of Treat-to-Target Strategy and Methotrexate Monotherapy Optimization in Patients with Established Rheumatoid Arthritis
René-Marc Flipo¹, Cécile Gaujoux-Viala², Christophe Hudry^3,4, Elena Zinovieva⁵, Eric Leutenegger⁶ and Hélène Herman-Demars⁵, ¹Rheumatology Department, Lille University Hospital Roger Salengro, Lille, France, ²Rheumatology Department, University Hospital of Nîmes and EA2415, Montpellier University, Nîmes, France, ³Rheumatology, Cochin Hospital, Paris, France, ⁴Rheumatology Institute, 75008, France, ⁵Medical Department Nordic Pharma, Paris, France, ⁶GECEM, Montrouge, France
Background/Purpose: Current guidelines consider MTX as initial gold standard treatment for patients (pts) with RA. They also propose various strategies for MTX inadequate responders, among…
Abstract Number: 2484 • 2016 ACR/ARHP Annual Meeting
Real World Treat to Target Strategy in Rheumatoid Arthritis: Radiograph and MRI Outcomes in Three Cohorts with 18 Month Follow up
Paul Bird¹, Maureen Rischmueller², Marie Feletar³, Gail Grant⁴, Margaret P. Staples⁵ and Stephen Hall⁶, ¹Medicine, University of New South Wales, Sydney, NSW, Australia, ²Rheumatology, The Queen Elizabeth Hospital, Adelaide, Australia, ³Department of Epidemiology and Preventive Medicine, Monash University, Dandenong, Australia, ⁴Emeritus Research, Malvern East, Australia, ⁵Monash Department of Clinical Epidemiology, Cabrini Institute and Monash University, Malvern, Australia, ⁶Cabrini Health and Monash University, Melbourne, VIC, Australia
Background/Purpose: The Treat to Target (TTT) model is well established in the treatment of rheumatic disease. Achieving DAS remission is one of the primary goals…
Abstract Number: 2555 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Conventional and Targeted Synthetic Disease-Modifying Antirheumatic Drugs As Well As Glucocorticoids: A Systematic Literature Review Informing the 2016 Update of the Eular Recommendations for the Management of Rheumatoid Arthritis
Katerina Chatzidionysiou¹, Sharzad Emamikia², Jackie L. Nam³, Sofia Ramiro⁴, Josef Smolen⁵, Désirée van der Heijde⁶, Maxime Dougados⁷, Johannes WJ Bijlsma⁸, Gerd Burmester⁹, Marieke Scholte-Voshaar¹⁰, Ronald van Vollenhoven^11,12 and Robert Landewé¹³, ¹Karolinska Institute, Stockholm, Sweden, ²Department of Medicine, Karolinska Institute, Stockholm, Sweden, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁷Paris Descartes University, Paris, France, ⁸Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁹Charité University Hospital, Berlin, Germany, ¹⁰EULAR Standing Committee of People with Arthritis/Rheumatism in Europe, Zurich, Switzerland, ¹¹Amsterdam Rheumatology Center, Amsterdam, Netherlands, ¹²Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ¹³Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: To inform the task force for the 2016 update of the EULAR recommendations for the management of RA on the evidence regarding the efficacy…
Abstract Number: 97 • 2016 ACR/ARHP Annual Meeting
Effects of DMARD Tapering on Treatment Costs and Work Productivity in Rheumatoid Arthritis Patients- an Analysis from the Prospective Randomized Controlled Retro- Study
Melanie Hagen¹, Camille P Figueiredo², Jayme Fogagnolo Cobra³, Judith Haschka⁴, Michaela Reiser⁵, Matthias Englbrecht⁶, Axel J. Hueber⁷, Bernhard Manger⁶, Arnd Kleyer⁸, Stephanie Finzel⁹, Hans-Peter Tony¹⁰, Stefan Kleinert¹¹, Joerg Wendler¹², Florian Schuch¹², Monika Ronneberger¹², Martin Feuchtenberger¹³, Martin Fleck¹⁴, Karin Manger¹⁵, Wolfgang Ochs¹⁶, Matthias Schmitt-Haendle¹⁷, H.-M. Lorenz¹⁸, HG Nüßlein¹⁹, R Alten²⁰, Joerg C. Henes²¹, Klaus Krüger²², Georg Schett⁷ and Juergen Rech⁷, ¹Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany, ²Rheumatology Division, Faculdade de Medicina da USP, São Paulo, Brazil, ³Instituto de Reumatologia de Sao Paolo, Sao Paolo, Brazil, ⁴Medical Department II, St. Vincent Hospital, the VINFORCE Study Group, Academic Teaching Hospital of Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁵Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ⁶Department of Internal Medicine 3, Rheumatology & Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁷Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁸Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁹Rheumatology and Clinical Immunology, University Medical Center Freiburg, Freiburg, Freiburg, Germany, ¹⁰Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Würzburg, Germany, ¹¹Rheumatologische Schwerpunktpraxis Erlangen, Erlangen, Germany, ¹²Schwerpunktpraxis Rheumatologie, Erlangen, Germany, ¹³Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, ¹⁴Department of Internal Medicine I, University of Regensburg, 93042 Regensburg, Germany, ¹⁵Rheumatology Practice Bamberg, Bamberg, Germany, ¹⁶Internistisch-rheumatologische Praxisgemeinschaft Bayreuth, Bayreuth, Germany, ¹⁷Rheumatology Practice, Bayreuth, Germany, Bayreuth, Germany, ¹⁸Im Neuenheimer Feld 41, UNI-Klinikum Heidelberg, Medizinische Klinik,, Heidelberg, Germany, ¹⁹University of Erlangen, Nürnberg, Germany, ²⁰Rheumazentrum Ruhrgebiet, Herne, Germany, ²¹Department of Internal Medicine II, Division of Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, ²²Praxiszentrum St. Bonifatius, München, Germany
Effects of DMARD Tapering on Treatment Costs and Work Productivity in Rheumatoid Arthritis Patients- an Analysis from the Prospective Randomized Controlled RETRO- Study Background/Purpose: Achieving remission…
Abstract Number: 472 • 2015 ACR/ARHP Annual Meeting
Quality Assessment in Clinical Management of Patients with Rheumatoid Arthritis. Are We Using the “Treat to Target” Strategy?
Jose Luis Andreu^1,2, Maria Auxiliadora Martin³, H Corominas⁴, Jose Javier Perez Venegas⁵, Jose Andres Roman Ivorra^6,7, Angel Gil⁸, Fernando Sánchez-Alonso⁹, Tamara Jiménez¹⁰ and Miguel Angel Sánchez-Ruiz¹⁰, ¹Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain, ²Rheumatology, HU Puerta de Hierro Majadahonda, Madrid, Spain, ³Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, ⁴CapiCAT group (Nailfold Capillaroscopy group from the Catalan Society for Rheumatology)., Catalonia, Spain, ⁵Rheumatology, Hospital de Jerez de la Frontera, Jerez de la Frontera, Spain, ⁶Rheumatology, H.U. P. La Fe, Valencia, Spain, ⁷Servicio de Reumatología, Servicio de Reumatología Hospital Universitario La Fe, Valencia, Spain, ⁸Cátedra de Resultados en Salud, Universidad Rey Juan Carlos, Madrid, Spain, ⁹Unidad de Investigación. Sociedad Española de Reumatología, Madrid, Spain, ¹⁰Universidad Rey Juan Carlos, Madrid, Spain
Background/Purpose: The current paradigm of optimal clinical management of patients with rheumatoid arthritis (RA) recommends reaching a state of remission or low activity of the disease,…
Abstract Number: 1044 • 2015 ACR/ARHP Annual Meeting
Many Patients with Early Rheumatoid Arthritis Want Triple Therapy: An Analysis Combining Comparative Effectiveness Research and Patients Preferences to Inform Treatment Recommendations
Glen S. Hazlewood^1,2, Claire Bombardier³, George A. Tomlinson⁴ and Deborah Marshall⁵, ¹Institute of Health, Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴Medicine, University Health Network, Toronto, ON, Canada, ⁵University of Calgary, Calgary, AB, Canada
Background/Purpose: Growing evidence supports the efficacy of triple therapy (methotrexate + sulphasalazine + hydroxychloroquine) for controlling disease activity in patients with early rheumatoid arthritis (ERA),…
Abstract Number: 2407 • 2014 ACR/ARHP Annual Meeting
Early Treatment in Rheumatoid Arthritis and Its Effect on Patient Outcomes
Laurent Chanroux and Joan Casellas, Therapy Watch, The Research Partnership, London, United Kingdom
Background/Purpose: It is generally thought that the early treatment of patients with rheumatoid arthritis (RA) leads to improved patient outcomes over time. Our study aims…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].